Mark Watkins, DO
Adult Medicine · Philadelphia, PANPI 1336226166
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $33,115 of the $53,923 with a category attached, or 61.4%. 12 manufacturers reported payments, led by Gilead at 56.0% of the total. Reporting peaked in 2019 at $26,768 and has fallen 93.5% since, to $1,746 in 2025. Among adult medicine clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 493 payments — averaging $109.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$30K
- Viiv Healthcare Company$21K
- Merck$772
- Johnson & Johnson$552
- Janssen Products, LP$424
- Theratechnologies Inc.$324
- plus $544 from 6 others
Across 1 payment — averaging $12,970 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Viiv Healthcare Company$13K
What the payments were for
- Consulting fees$4,5478%
- Speaking & faculty fees$33,11561%
- Travel & lodging$6,01411%
- Food & beverage$9,88518%
- Education$3621%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 174 | $30,196 |
| Viiv Healthcare Company | 201 | $21,113 |
| Merck | 40 | $772 |
| Johnson & Johnson | 33 | $552 |
| Janssen Products, LP | 5 | $424 |
| Theratechnologies Inc. | 17 | $324 |
| Lilly USA, LLC | 7 | $257 |
| Novo Nordisk | 12 | $201 |
| AbbVie | 1 | $26 |
| Abbott | 1 | $24 |
| Dexcom, Inc. | 1 | $19 |
| EMD Serono, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$53,923 in reported general payments places this provider in the 95th percentile of 52 adult medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 175 | $730,351 |
| RukobiaFostemsavir Tromethamine | 48 | $537,106 |
| CabenuvaCabotegravir/Rilpivirine | 69 | $470,498 |
| JulucaDolutegravir/Rilpivirine | 108 | $428,429 |
| TivicayDolutegravir Sodium | 118 | $368,005 |
| DovatoDolutegravir Sodium/Lamivudine | 71 | $228,591 |
| PifeltroDoravirine | 83 | $165,509 |
| DescovyEmtricitabine/Tenofov Alafenam | 73 | $161,578 |
| Egrifta SvTesamorelin Acetate | 21 | $150,235 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 35 | $130,201 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 25 | $96,030 |
| EdurantRilpivirine Hcl | 59 | $82,617 |
| PrezcobixDarunavir/Cobicistat | 29 | $81,336 |
| OzempicSemaglutide | 68 | $79,186 |
| MounjaroTirzepatide | 72 | $75,613 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Viiv Healthcare CompanyRukobia, Cabenuva, Juluca, Tivicay, Dovato | $21,113 | $2,162,830449 claims |
| GileadBiktarvy, Descovy, Genvoya | $30,196 | $955,258259 claims |
| MerckPifeltro, Isentress Hd | $772 | $214,160103 claims |
| Theratechnologies Inc.Egrifta Sv | $324 | $150,23521 claims |
| Lilly USA, LLCMounjaro, Trulicity | $257 | $124,225112 claims |
| Johnson & JohnsonPrezcobix | $552 | $81,33629 claims |
| Novo NordiskOzempic | $201 | $79,18668 claims |
| AbbVieLinzess | $26 | $5,72811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 52 adult medicine providers in Pennsylvania.
Other adult medicine in Philadelphia
- Peter HonigPhiladelphia$140K
- Emily ScaruzziPhiladelphia$16K
- Harvey SpectorPhiladelphia$15K
- Paul lePhiladelphia$568
- Hadijatou JarraPhiladelphia$528
- Amy Orloff-FinePhiladelphia$469
- Agnes SimmonsPhiladelphia$439
- Hussein SafaPhiladelphia$389
- Nataliya NovykovaPhiladelphia$327
- Edward StraussPhiladelphia$277
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.